CBAY News and Press, CymaBay Therapeutics Inc. From 08/11/22

CymaBay Therapeutics press release ( NASDAQ: CBAY ): Q2 GAAP EPS of -$0.31 misses by $0.01 . Shares +5% . Held $170.8 million in cash, cash equivalents and investments as of June 30, 2022. We believe that cash and investments on hand are sufficient to fund Cyma...

Enrollment completed in RESPONSE with 193 patients enrolled in over 20 countries Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focuse...

NEWARK, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live aud...

NEWARK, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the completion of enrollment for RESPONSE, a glo...

Results from the phase 3 RESPONSE study, which is using Seladelpar for the treatment of patients with primary biliary Cholangitis, are expected in 2023. PBC patients treated with Seladelpar over a 2-year period saw a decrease in GLOBE PBC Score and improved transplant-free survival. ...

Gainers:Scholar Rock Holding  (SRRK) +6%. Science 37 Holdings (SNCE) +6%. Arcimoto (FUV) +5%. Hyzon Motors (HYZN) +4%. SoundHound (SOUN) +4%. Losers: Guardant Health (GH) -5%. CymaBay Therapeutics  (CBAY) -5%. Polestar Automotive Holding  (PSNY) -5%. Adagio Therapeutics, (...

Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival NEWARK, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver a...

NEWARK, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that multiple seladelpar presentations will be d...

Penny stocks can be your greatest asset or worst enemy, depending on how you trade them. Their low prices lend themselves to considerable gain potential, and I’m not just talking 5 or 10%. Almost daily, we see stocks under $5 explode by 50% or more…yes, 50% or more. But with t...

CymaBay Therapeutics (NASDAQ:CBAY) stock edge higher after disclosing that its CEO Sujal Shah bought 51.301K shares of common stock on 6 June. As per regulatory filing, shares were purchased at $1.95, for total transaction size of $100K. For further details see: CymaBay Therapeutic...